Glythera Appoints Chief Scientific Officer and Strengthens SAB
Dr Robert Lutz
Glythera Limited is pleased to announce the appointment of Dr Robert Lutz as Chief Scientific Officer. Dr Lutz will lead the advancement of Glythera’s portfolio of Antibody Drug Conjugates (ADCs) in the treatment of difficult-to-treat cancers. In addition, Glythera has appointed Dr Jon Roffey to the company’s Scientific Advisory Board (SAB).
With more than 25 years’ experience, Dr Lutz was previously Vice President of Translation Research and Development at ImmunoGen Inc., where he was responsible for all early-stage ADC development programs and gained further experience in directing the clinical pharmacology, biomarkers, pharmacology and toxicology departments. While at ImmunoGen, Dr Lutz was responsible for bringing eight of ImmunoGen’s candidate ADC products into development and included being the research lead for Kadcyla®.
Dr Jon Roffey joins Glythera’s SAB from Cancer Research Technology (CRT), Cancer Research UK’s Commercial Partnerships team, where he has been working since 2006, initially as medicinal chemistry group leader and, latterly, with responsibility for forging drug-discovery alliances between academia and industry. As a medicinal chemist by training, Dr Roffey has had active involvement in a wide variety of therapeutic areas, including the development of ADCs in cancer.
Dr Dave Simpson, Chief Executive Officer, Glythera, said: “Robert Lutz’s experience in ADC development will be a great asset as Glythera continues to develop our pipeline of cancer treatments. With Robert’s appointment as CSO, and the addition of Jon Roffey to our Scientific Advisory Board, we start 2018 in a strengthened position as developers of the very best novel agents and targeted treatments, aiming to improve the lives of patients living with cancers that are the hardest to treat.”
Cellular Valve Structure Opens Up Potential Novel TherapiesNews
Biochemists have determined the detailed structure of a volume-regulated chloride channel. This cellular valve is activated in response to swelling to prevent the cell from bursting. The protein also plays an important role in the uptake of chemotherapeutics and the release of neurotransmitters after a stroke. The controlled regulation of its activity thus opens up a promising strategy for novel therapies.READ MORE
Computation and Chemistry Combine to Create World-First Auxetic ProteinNews
A team of chemists at the University of California, San Diego (UCSD) has now designed a two-dimensional protein crystal that toggles between states of varying porosity and density. This is a first in biomolecular design that combined experimental studies with computation done on supercomputers. The research, published in April 2018 in Nature Chemistry, could help create new materials for renewable energy, medicine, water purification, and more.
Stem Cell Signaling Drives Mammary Gland DevelopmentNews
New research illuminates the biology of breast tissue development and may pave the way to new strategies for diagnosing or even treating cancer.READ MORE